Role of sublingual asenapine in treatment of schizophrenia

References

• VolavkaJCitromeLOral antipsychotics for the treatment of schizophrenia: Heterogeneity in efficacy and tolerability should drive decision-makingExpert Opin Pharmacother200910121917192819558339
   PubMed Web of Science ®Google Scholar
• Saphris (asenapine) sublingual tablets. Merck and Company Inc. Product labelling, revised January 2011. Available from: http://www.spfiles.com/pisaphrisv1.pdf. Accessed April 6, 2011
   Google Scholar
• KaneJMCohenMZhaoJAlphsLPanagidesJEfficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophreniaJ Clin Psychopharmacol201030210611520520283
   PubMed Web of Science ®Google Scholar
• PotkinSGCohenMPanagidesJEfficacy and tolerability of asenapine in acute schizophrenia: A placebo- and risperidone-controlled trialJ Clin Psychiatry200768101492150017960962
   PubMed Web of Science ®Google Scholar
• KaneJMMackleMSnow-AdamiLZhaoJSzegediAPanagidesJA randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatmentJ Clin Psychiatry201172334935521367356
   PubMed Web of Science ®Google Scholar
• SchoemakerJNaberDVrijlandPPanagidesJEmsleyRLong-term assessment of asenapine vs. olanzapine in patients with schizophrenia or schizoaffective disorderPharmacopsychiatry201043413814620205074
   PubMed Web of Science ®Google Scholar
• ChapelSHutmacherMMHaigGExposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongationJ Clin Pharmacol200949111297130819843656
   PubMed Web of Science ®Google Scholar
• ChapelSHutmacherMMBockbraderHde GreefRLalondeRLComparison of QTc data analysis methods recommended by the ICH E14 guidance and exposure-response analysis: Case study of a thorough QT study of asenapineClin Pharmacol Ther2011891758021107314
   PubMed Web of Science ®Google Scholar
• CazorlaPPanagidesJZhaoJLong-term efficacy of asenapine in people with persistent negative symptoms of schizophreniaInt J Neuropsychopharmacol201013Suppl 1215
   Google Scholar
• DubovskySLFroboseCPhiriPPanagidesJShort-term tolerability, safety, and pharmacokinetic profile of asenapine in older patients with psychosisSchizophr Res20101172–3263264
   Web of Science ®Google Scholar
• DubovskySFroboseCPhiriPPanagidesJAsenapine: Short-term tolerability, safety, and pharmacokinetic profile in older patients with psychosisEur Neuropsychopharmacol201020Suppl 3S489S490
   Web of Science ®Google Scholar
• MeltzerHCohenMSnow-AdamiLLong-term safety and maintenance of effect of asenapine in patients with acute exacerbation of schizophreniaEur Neuropsychopharmacol200919Suppl 3S536S537
   Web of Science ®Google Scholar
• SchoemakerJNaberDJansenWPanagidesJEmsleyRSafety and efficacy of long-term asenapine versus olanzapine in schizophrenia or schizoaffective disorder patientsEur Psychiatry201025Suppl 11621
   Google Scholar
• SchoemakerJStetLNaberDPanagidesJEmsleyRSafety and efficacy of long-term asenapine versus olanzapine in schizophrenia or schizoaffective disorder patientsInt J Neuropsychopharmacol201013Suppl 1238
   Google Scholar
• ZhaoJVan HoekPCazorlaPWeight change and metabolic effects of asenapine in placebo- or olanzapine-controlled studiesNeuropsychopharmacology201035Suppl 1S322
   Google Scholar
• PotkinPPhiriPZhaoJA pooled analysis of the effects of asenapine on the persistent negative symptoms of schizophreniaNeuropsychopharmacology201035Suppl 1S213
   Google Scholar
• SzegediAVerweijPVan DuijnhovenWEfficacy of asenapine for schizophrenia: Comparison with placebo and comparative efficacy of all atypical antipsychotics using all available head-to-head randomized trials using meta-analytical techniquesNeuropsychopharmacology201035Suppl 1S105
   Google Scholar
• Schering-PloughEfficacy and safety of asenapine compared with olanzapine in patients with persistent negative symptoms of schizophrenia Study NCT00145496. Available from: http://www.clinicaltrials.gov/ct2/show/record/NCT00145496. Accessed April 6, 2011
   Google Scholar
• Schering-PloughTo determine long term efficacy and safety of asenapine in schizophrenic patient population Study NCT00150176. Available from: http://www.clinicaltrials.gov/ct2/show/record/NCT00150176. Accessed April 6, 2011
   Google Scholar
• Schering-PloughLong-term efficacy and safety of asenapine using haloperidol as a positive control Study NCT00156065. Available from: http://www.clinicaltrials.gov/ct2/show/record/NCT00156065. Accessed April 6, 2011
   Google Scholar
• Schering-Plough. 6-month extension trial of asenapine with olanzapine in negative symptom patients who completed the first 6-month trial Study NCT00174265. Available from: http://www.clinicaltrials.gov/ct2/show/record/NCT00174265. Accessed April 6, 2011
   Google Scholar
• Schering-Plough6-month extension trial of asenapine with olanzapine in negative symptom patients who completed the protocol 25543 Study NCT00265343. Available from: http://www.clinicaltrials.gov/ct2/show/record/NCT00265343. Accessed April 6, 2011
   Google Scholar
• Schering-PloughStudy of asenapine in elderly subjects with psychosis Study NCT00281320. Available from: http://www.clinicaltrials.gov/ct2/show/record/NCT00281320. Accessed April 6, 2011
   Google Scholar
• Schering-PloughA trial to determine whether two differing strength tablets (3 × 5 mg versus 1 × 15 mg) of sublingually Org 5222 (asenapine) are safe and equal in subjects with schizophrenia or schizoaffective disorder Study NCT01101464. Available from: http://www.clinicaltrials.gov/ct2/show/record/NCT01101464. Accessed April 6, 2011.
   Google Scholar
• CitromeLAsenapine for schizophrenia and bipolar disorder: A review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychoticInt J Clin Pract200963121762178419840150
   PubMed Web of Science ®Google Scholar
• United States Food and Drug AdministrationSaphris (asenapine) sublingual tablets Briefing book. July 30, 2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting-Materials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM173877.pdf. Accessed April 6, 2011
   Google Scholar
• Schering-Plough Research InstituteSaphris (asenapine) sublingual tablets. Briefing document (background package) July 30, 2009. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM173876.pdf. Accessed April 6, 2011
   Google Scholar
• US Food and Drug AdministrationDrug approval package for Saphris (asenapine) tablet Updated 18 December 2009. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022117s000TOC.cfm. Accessed April 6, 2011.
   Google Scholar
• GerritsMde GreefRPeetersPEffect of absorption site on the pharmacokinetics of sublingual asenapine in healthy male subjectsBiopharm Drug Dispos2010315–635135720549835
   PubMed Web of Science ®Google Scholar
• ShahidMWalkerGBZornSHWongEHAsenapine: A novel psychopharmacologic agent with a unique human receptor signatureJ Psychopharmacol2009231657318308814
   PubMed Web of Science ®Google Scholar
• ShayeganDKStahlSMAtypical antipsychotics: Matching receptor profile to individual patient’s clinical profileCNS Spectr20049Suppl 1161415475871
   PubMed Web of Science ®Google Scholar
• BallazSJAkilHWatsonSJThe 5-HT7 receptor: Role in novel object discrimination and relation to novelty-seeking behaviorNeuroscience2007149119220217869441
   PubMed Web of Science ®Google Scholar
• StahlSMThe serotonin-7 receptor as a novel therapeutic targetJ Clin Psychiatry201071111414141521114946
   PubMed Web of Science ®Google Scholar
• De GreefRMaloneyAOlsson-GisleskogPSchoemakerJPanagidesJDopamine D2 occupancy as a biomarker for antipsychotics: Quantifying the relationship with efficacy and extrapyramidal symptomsAAPS J201113112113021184291
   PubMed Web of Science ®Google Scholar
• CitromeLCompelling or irrelevant? Using number needed to treat can help decideActa Psychiatr Scand2008117641241918479317
   PubMed Web of Science ®Google Scholar
• Schering-PloughEfficacy and safety of asenapine using an active control in subjects with schizophrenia or schizoaffective disorder Study NCT00212784. Available from: http://www.clinicaltrials.gov/ct2/show/record/NCT00212784. Accessed April 6, 2011
   Google Scholar
• AlphsLPanagidesJLancasterSAsenapine in the treatment of negative symptoms of schizophrenia: Clinical trial design and rationalePsychopharmacol Bull2007402415317514185
   PubMed Web of Science ®Google Scholar
• Schering-PloughEfficacy and safety of asenapine compared with olanzapine in patients with persistent negative symptoms of schizophrenia Study NCT00212836. Available from: http://www.clinicaltrials.gov/ct2/show/record/NCT00212836. Accessed April 6, 2011
   Google Scholar
• FribergLEDe GreefRKerbuschTKarlssonMOModeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophreniaClin Pharmacol Ther2009861849119387434
   PubMed Web of Science ®Google Scholar
• VentimigliaJKalaliAHCitromeLA review of new atypical antipsychotic launches in the United StatesPsychiatry (Edgmont)2010712131521274390
   PubMedGoogle Scholar
• CitromeLIloperidone, asenapine, and lurasidone: A brief overview of 3 new second-generation antipsychoticsPostgrad Med2011123215316221474903
   PubMed Web of Science ®Google Scholar
• CitromeLLurasidone for schizophrenia: A brief review of a new second-generation antipsychoticClin Schizophr Relat Psychoses20114425125721177242
   PubMedGoogle Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• LeuchtSKomossaKRummel-KlugeCA meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophreniaAm J Psychiatry2009166215216319015230
   PubMed Web of Science ®Google Scholar
• LeuchtSArbterDEngelRRKisslingWDavisJMHow effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trialsMol Psychiatry200914442944718180760
   PubMed Web of Science ®Google Scholar